Shoa L Clarke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5550314/publications.pdf Version: 2024-02-01



SHOAL CLARKE

#	Article	IF	CITATIONS
1	Editorial commentary: A new era for preventive cardiology. Trends in Cardiovascular Medicine, 2022, 32, 195-197.	4.9	0
2	<i>ZEB2</i> Shapes the Epigenetic Landscape of Atherosclerosis. Circulation, 2022, 145, 469-485.	1.6	31
3	Coronary Artery Disease Risk of Familial Hypercholesterolemia Genetic Variants Independent of Clinically Observed Longitudinal Cholesterol Exposure. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003501.	3.6	6
4	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	10.3	36
5	Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management. EBioMedicine, 2022, 80, 104038.	6.1	7
6	Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations. Current Cardiology Reports, 2022, 24, 1169-1177.	2.9	10
7	The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case. Current Opinion in Lipidology, 2021, 32, 89-95.	2.7	10
8	Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries. American Journal of Cardiology, 2021, 148, 157-164.	1.6	48
9	Combining Clinical and Polygenic Risk Improves Stroke Prediction Among Individuals With Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, e003168.	3.6	24
10	Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry. Circulation Genomic and Precision Medicine, 2021, 14, e003354.	3.6	21
11	The Propagation of Racial Disparities in Cardiovascular Genomics Research. Circulation Genomic and Precision Medicine, 2021, 14, e003178.	3.6	14
12	Time to Relax the 40-Year Age Threshold for Pharmacologic Cholesterol Lowering. Journal of the American College of Cardiology, 2021, 78, 1965-1967.	2.8	3
13	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	27.8	353
14	Cardiorespiratory Fitness, Body Mass Index, and Markers of Insulin Resistance in Apparently Healthy Women and Men. American Journal of Medicine, 2020, 133, 825-830.e2.	1.5	14
15	Abstract 13601: Risk of Coronary Artery Disease Associated With Familial Hypercholesterolemia Genetic Variants is Independent of Historical Low-density Lipoprotein Cholesterol Exposure. Circulation, 2020, 142, .	1.6	0
16	Abstract 012: Performance of Polygenic Risk Scores for Coronary Artery Disease in the Million Veteran Program. Circulation, 2019, 139, .	1.6	1
17	Genome-Wide Association Studies of Coronary Artery Disease: Recent Progress and Challenges Ahead. Current Atherosclerosis Reports, 2018, 20, 47.	4.8	24
18	Erosion of Conserved Binding Sites in Personal Genomes Points to Medical Histories. PLoS Computational Biology, 2016, 12, e1004711.	3.2	7

SHOA L CLARKE

#	Article	IF	CITATIONS
19	PRISM offers a comprehensive genomic approach to transcription factor function prediction. Genome Research, 2013, 23, 889-904.	5.5	32
20	The Enhancer Landscape during Early Neocortical Development Reveals Patterns of Dense Regulation and Co-option. PLoS Genetics, 2013, 9, e1003728.	3.5	33
21	Coding exons function as tissue-specific enhancers of nearby genes. Genome Research, 2012, 22, 1059-1068.	5.5	202
22	Human Developmental Enhancers Conserved between Deuterostomes and Protostomes. PLoS Genetics, 2012, 8, e1002852.	3.5	55
23	Control of pelvic girdle development by genes of the Pbx family and <i>Emx2</i> . Developmental Dynamics, 2011, 240, 1173-1189.	1.8	32
24	GREAT improves functional interpretation of cis-regulatory regions. Nature Biotechnology, 2010, 28, 495-501.	17.5	3,789